Profile


A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
12/12/2013 - 12/12/2019 (Co-PI)
PI: Vaishali Sanchorawala, MBBS
Academic Myeloma Consortium


Center for Innovation in Point of Care Technologies for the Future of Cancer Care
07/01/2012 - 06/30/2017 (SP Co-PI of Sub-Project / SP)
PI: Catherine M. Klapperich, PhD
NIH/National Institute of Biomedical Ima
5U54EB015403-04

A Phase II Trial of MRD (Melphalan, Revilimid, and Dexamethasone) for Patients with AL Amyloidosis
02/11/2008 - 09/18/2015 (PI)
Celgene Corporation


Personnel agreement for research services of Mary Brophy
01/01/2013 - 09/30/2014 (PI)
Boston VA Research Institute, Inc. Allergan Sales Inc


Personnel agreement for research services of Louis Fiore
10/01/2012 - 09/30/2014 (PI)
Boston VA Research Institute, Inc.


Incidence of abnormal free light chains and other markers of light chain amyloidosis in veterans exposed to agent orange: a Pilot Study
02/22/2013 - 06/30/2014 (PI)
National Academy of Sciences Department of VA


Personnel Agreement for Research Services of Deborah Govan
10/01/2012 - 12/31/2012 (PI)
Boston VA Research Institute, Inc.


Personnel Agreement for Research Services of Deborah Govan
10/01/2009 - 09/30/2012 (PI)
VA Boston Healthcare System


A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients with AL Amyloidosis
02/02/2004 - 02/13/2012 (PI)
Celgene Corporation


m2A4 Activity Study
06/01/2011 - 01/31/2012 (PI)
Elan Pharmaceuticals, Inc.



Signaling Pathways in Stages of Tumorigenesis
01/01/2010 - 06/30/2014 (PI)
Tufts University NIH-NIEHS

Evaluation of Link Medicine Corporation's Compound in AL Amyloidosis
06/01/2010 - 11/30/2012 (PI)
Link Medicine Corporation

Patient Navigator
06/01/2008 - 10/31/2012 (PI)
Kohlberg Foundation

A Mouse Model for the Rare Plasma Cell Disease AL Amyloidosis
05/10/2010 - 04/30/2012 (PI)
NIH-NIDDK

Multistep Lymphomagenesis Tumorigenesis in Transgenic mice: Protein Kinase Ck2
06/13/2006 - 04/30/2012 (PI)
NIH-NCI

Signaling Pathways in Stages of Mammary Tumorigenesis
09/01/2008 - 12/31/2009 (PI)
Trustees of Boston University NIH-NIEHS

American Cancer Society/BMC Patient Navigation Program
07/01/2007 - 06/30/2009 (PI)
Mabel A. Horne Fund

Protein Kinase CK2: Identification of Regulatory Signaling Pathways and Development of CK2 Inhibitor
06/01/2006 - 05/31/2008 (PI)
Trustees of Boston University Avon Products Fdtn

Role of DN-GSK3 in Mammary Tumongenesis
07/01/2004 - 01/31/2008 (PI)
Department of Defense

Multistep Lymphomagenisis
05/15/1998 - 04/30/2006 (PI)
NIH-NCI

Showing 10 of 12 results. Show All Results


Yr Title Project-Sub Proj Pubs
2012 Research Project 2: Role of CK2 and the Wnt Signaling Pathway in the Progression 5P01ES011624-11-5 65
2012 CORE B: Animal Model Core 5P01ES011624-11-9002 65
2011 MS CHAR OF AMYLOIDOGENIC LIGHT CHAINS OF PTS DIAGNOSED W/PRIMARY AMYLOIDOSIS 5P41RR010888-15-5090 236
2011 Research Project 2: Role of CK2 and the Wnt Signaling Pathway in the Progression 5P01ES011624-10-5 65
2011 CORE B: Animal Model Core 5P01ES011624-10-9002 65
2010 Research Project 2: Role of CK2 and the Wnt Signaling Pathway in the Progression 5P01ES011624-09-5 65
2010 CORE B: Animal Model Core 5P01ES011624-09-9002 65
2010 MS CHAR OF AMYLOIDOGENIC LIGHT CHAINS OF PTS DIAGNOSED W/PRIMARY AMYLOIDOSIS 5P41RR010888-14-6788 236
2010 A Mouse Model for the Rare Plasma Cell Disease AL Amyloidosis 1RC1DK090696-01 4
2010 Multistep Lymphomagenesis/Tumorigenesis in Transgenic Mice: Protein Kinase Ck2 5R01CA071796-13 22
Showing 10 of 48 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med. 2015 May; 7(5):688.View Related Profiles. PMID: 25940533; PMCID: PMC4492824; DOI: 10.15252/emmm.201505318;.
  2. Renteria AS, Sanchorawala V, Niehaus ED, Sun F, Semigran MJ, Seldin DC. Serum free light chain trends between orthotopic heart transplantation and auto-SCT in patients with AL amyloidosis. Bone Marrow Transplant. 2015 Jun; 50(6):868-9.View Related Profiles. PMID: 25751645; DOI: 10.1038/bmt.2015.9;.
  3. Greene MJ, Klimtchuk ES, Seldin DC, Berk JL, Connors LH. Cooperative stabilization of transthyretin by clusterin and diflunisal. Biochemistry. 2015 Jan 20; 54(2):268-78.View Related Profiles. PMID: 25478940; PMCID: PMC4303310; DOI: 10.1021/bi5011249;.
  4. Sikora JL, Logue MW, Chan GG, Spencer BH, Prokaeva TB, Baldwin CT, Seldin DC, Connors LH. Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt). Hum Genet. 2015 Jan; 134(1):111-21.View Related Profiles. PMID: 25367359; PMCID: PMC4282974; DOI: 10.1007/s00439-014-1499-0;.
  5. Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med. 2014 Nov; 6(11):1493-507.View Related Profiles. PMID: 25319546; PMCID: PMC4237473; DOI: 10.15252/emmm.201404190;.
  6. Fu J, Seldin DC, Berk JL, Sun F, O''Hara C, Cui H, Sanchorawala V. Lymphadenopathy as a manifestation of amyloidosis: a case series. Amyloid. 2014 Dec; 21(4):256-60.View Related Profiles. PMID: 25208081; DOI: 10.3109/13506129.2014.958610;.
  7. Freeman B, Brauneis D, Seldin DC, Quillen K, Sloan JM, Renteria AS, Shelton AC, Teschner T, Finn KT, Sanchorawala V. Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis. Bone Marrow Transplant. 2014 Oct; 49(10):1345-6.View Related Profiles. PMID: 24955784; DOI: 10.1038/bmt.2014.132;.
  8. Lee SY, Sanchorawala V, Seldin DC, Mark Sloan J, Andrea N, Quillen K. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. Amyloid. 2014 Sep; 21(3):149-53.View Related Profiles. PMID: 24779777; DOI: 10.3109/13506129.2014.900486;.
  9. Lichtman EI, Seldin DC, Shelton A, Sanchorawala V. Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis. Am J Hematol. 2014 Jul; 89(7):706-8.View Related Profiles. PMID: 24668858; DOI: 10.1002/ajh.23722;.
  10. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013 Dec 25; 310(24):2658-67.View Related Profiles. PMID: 24368466; PMCID: PMC4139164; DOI: 10.1001/jama.2013.283815;.
Showing 10 of 186 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 28 publications over 10 distinct years, with a maximum of 11 publications in 2008

YearPublications
19811
19821
19852
19861
19881
20042
20056
20071
200811
20112
Contact for Mentoring: